Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.

Proclemer A, Muser D, Campana A, Zoni-Berisso M, Zecchin M, Locatelli A, Brieda M, Gramegna L, Santarone M, Chiodi L, Mazzone P, Rebellato L, Facchin D.

Int J Cardiol. 2013 Sep 30;168(2):1416-21. doi: 10.1016/j.ijcard.2012.12.042. Epub 2012 Dec 31.

PMID:
23287697
2.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

3.

The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.

Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM.

Ital Heart J. 2005 Mar;6(3):272-80.

PMID:
15875520
4.

Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07.

Proclemer A, Ghidina M, Gregori D, Facchin D, Rebellato L, Fioretti P, Brignole M.

Europace. 2009 Apr;11(4):465-75. doi: 10.1093/europace/eun370. Epub 2009 Jan 9.

PMID:
19136490
5.

Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ.

JAMA. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182.

6.

Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798. Epub 2012 Jun 8.

7.

Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.

Amit G, Suleiman M, Konstantino Y, Luria D, Kazatsker M, Chetboun I, Haim M, Gavrielov-Yusim N, Goldenberg I, Glikson M; Israeli Working Group on Pacing and Electrophysiology..

Europace. 2014 Aug;16(8):1175-80. doi: 10.1093/europace/euu015. Epub 2014 Feb 19.

PMID:
24554524
8.

Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.

Weeke P, Johansen JB, Jørgensen OD, Nielsen JC, Møller M, Videbæk R, Højgaard MV, Riahi S, Jacobsen PK.

Europace. 2013 Aug;15(8):1150-7. doi: 10.1093/europace/eut017. Epub 2013 Feb 13.

PMID:
23407630
9.

Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.

Kaiser DW, Tsai V, Heidenreich PA, Goldstein MK, Wang Y, Curtis J, Turakhia MP; National Cardiovascular Data Registry..

Heart Rhythm. 2015 Oct;12(10):2086-93. doi: 10.1016/j.hrthm.2015.05.010. Epub 2015 May 14.

10.

Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?

Siu CW, Pong V, Ho HH, Liu S, Lau CP, Li SW, Tse HF.

J Cardiovasc Electrophysiol. 2010 Mar;21(3):231-5. doi: 10.1111/j.1540-8167.2009.01609.x. Epub 2009 Oct 5.

PMID:
19804551
11.

Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.

Thijssen J, van den Akker van Marle ME, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van Erven L, Schalij MJ.

Pacing Clin Electrophysiol. 2014 Jan;37(1):25-34. doi: 10.1111/pace.12238. Epub 2013 Sep 2.

PMID:
23998638
12.

Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.

Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, Seifert B, Hürlimann D, Lehmkuhl HB, Noll G, Steffel J, Falk V, Lüscher TF, Hetzer R, Ruschitzka F.

Heart. 2013 Aug;99(16):1158-65. doi: 10.1136/heartjnl-2013-304185. Epub 2013 Jun 27.

PMID:
23813845
13.

Impact of the main implantable cardioverter-defibrillator trials for primary and secondary prevention in Italy: a survey of the national activity during the years 2001-2004.

Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM.

Pacing Clin Electrophysiol. 2006 Dec;29 Suppl 2:S20-8.

PMID:
17169129
14.

Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.

Forleo GB, Della Rocca DG, Papavasileiou LP, Panattoni G, Sergi D, Duro L, Mahfouz K, Magliano G, Santini L, Romeo F.

J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):779-84. doi: 10.2459/JCM.0b013e32834ae458.

PMID:
21941203
15.

Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):164-70. doi: 10.1161/CIRCEP.113.001217. Epub 2014 Jan 20. Review.

16.

[How many leads are needed for an ICD?].

Schaumann A, Gödde M, Tönnis T.

Herz. 2005 Nov;30(7):591-5. German.

PMID:
16333583
17.

Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study.

Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C.

J Cardiovasc Electrophysiol. 2014 Jan;25(1):52-9. doi: 10.1111/jce.12273. Epub 2013 Sep 24.

PMID:
24112717
18.

Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. "Routine Practice" data from the SEARCH MI registry.

Boriani G, Botto G, Lunati M, Proclemer A, Schmidt B, Erdogan A, Rauhe W, Biffi M, Santi E, Becker D, Messier M, Santini M.

BMC Cardiovasc Disord. 2012 Sep 11;12:72. doi: 10.1186/1471-2261-12-72.

19.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

20.

Appropriate therapies predict long-term mortality in primary and secondary prevention of sudden cardiac death.

Stabile G, D'Agostino C, Gallo P, Marrazzo N, Iuliano A, De Simone A, Turco P, Palella M, Donnici G, Ciardiello C, Napolitano G, Solimene F.

J Cardiovasc Med (Hagerstown). 2013 Feb;14(2):110-3. doi: 10.2459/JCM.0b013e3283511f5b.

PMID:
22367567

Supplemental Content

Support Center